Uncategorized
Aflibercept for AMD largely maintains visual gains through 212 weeks
Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the study results.In the four arms of the VIEW 1 trial, 1,217 patients with neovascular age-related macular degeneration were randomized to receive 0.5 mg intravitreal Eylea (aflibercept, Regeneron) injections every 4 weeks, 2 mg of aflibercept every 4 weeks, 2 mg of aflibercept every 8 weeks after three initial monthly doses, or 0.5 mg Lucentis (ranibizumab, Genentech) every 4 weeks. Mean best corrected visual acuity at baseline was (Read more...)